Abstract
An experimental tumor model was previously established in which BALB/c mice could survive the otherwise fatal intraperitoneal (i.p.) inoculation of BAMC-1 fibrosarcoma cells if the mice were treated with five sequential i.p. injections of OK-432 (a potent BRM) starting 2 days after tumor inoculation. In the present study, although a single i.p. injection of OK-432 alone on day 2 was not enough to cure the tumor-bearing mice, a combination therapy, an injection of OK-432 (5 mg/kg) on day 2 followed by injection of G-CSF (50 micrograms/kg) on day 3, could eradicate the tumor cells in more than 80% of the mice. In contrast to this ascites tumor model, solid tumors induced by intradermal transplantation of BAMC-1 tumor cells were resistant to the combined treatments with OK-432 and G-CSF, dying within 60 days. However, when these mice received a combined chemoimmunotherapy with cisplatin, OK-432, G-CSF and IL-2, starting on day 4, the tumors had regressed, and were completely eradicated. When the same treatment was started as late as day 8, no significant therapeutic effect was observed. Even at this advanced stage, however, it was found that a similar chemo-immunotherapy protocol using CAP-D (cyclophosphamide, epirubicin and DWA21...Continue Reading
References
Jan 1, 1992·Cancer Immunology, Immunotherapy : CII·K D YangM F Shaio
Sep 30, 1991·International Journal of Cancer. Journal International Du Cancer·Y MatsumotoI Azuma
Jan 1, 1991·Leukemia Research·M GadishI Fabian
Jan 1, 1991·Biotherapy·N BabaT Toge
Jan 1, 1991·International Journal of Immunopharmacology·M NanjoN Ishida
Dec 1, 1990·The Journal of Clinical Investigation·J M Alvaro-GraciaG S Firestein
Jan 1, 1986·Cancer Immunology, Immunotherapy : CII·M SaitoN Ishida
Aug 1, 1989·Journal of Medicinal Chemistry·P BithaH L Lindsay
Jan 1, 1989·Cancer Immunology, Immunotherapy : CII·H FukuiJ E Talmadge
May 1, 1989·Immunology Letters·H FukuiA Uchida
Aug 3, 1985·Lancet·M KatoD Mizuno
Jun 5, 1987·Science·S C Clark, R Kamen
Jan 5, 1986·Nature·S NagataH Nomura
Sep 1, 1986·Immunobiology·E PlatzerJ R Kalden
Apr 1, 1987·The Journal of Experimental Medicine·K WelteL M Souza
Aug 1, 1986·Immunology Letters·M NagamutaI Urushizaki
Jan 1, 1985·International Journal of Immunopharmacology·O IchimuraN Ishida
Jun 1, 1983·Cellular Immunology·M SaitoN Ishida
Feb 15, 1984·International Journal of Cancer. Journal International Du Cancer·M SaitoN Ishida
Jan 15, 1984·Cancer·Y Watanabe, T Iwa
Jul 15, 1983·International Journal of Cancer. Journal International Du Cancer·A Uchida, M Micksche
Feb 1, 1980·Cancer·A Uchida, T Hoshino
Jan 1, 1994·International Journal of Immunopharmacology·M InoueM Kondo
Jan 1, 1993·Cancer Immunology, Immunotherapy : CII·Y MoriyaN Ishida
Jan 1, 1994·International Journal of Immunopharmacology·E UetaT Osaki
May 4, 1993·Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy·M OkamotoM Sato
Citations
Jun 5, 2008·The Journal of Clinical Investigation·Laurence ZitvogelGuido Kroemer
Mar 3, 1999·Bioscience, Biotechnology, and Biochemistry·A TsuzukiT Yadomae
Mar 23, 2002·Cancer Treatment Reviews·G G GomezC A Kruse